卡马替尼联合吉非替尼治疗EGFR突变伴MET失调NSCLC的Ib/II期研究
该Ib/II期研究评估卡马替尼联合吉非替尼在EGFR突变且MET失调(扩增/过表达)的NSCLC患者中的安全性和疗效,这些患者在接受EGFR-TKI治疗期间出现疾病进展。总体客观缓解率(ORR)为27%,MET基因拷贝数≥6的患者II期ORR达47%,常见药物相关不良事件为恶心、外周水肿、食欲下降和皮疹。
要点
- II期推荐剂量为卡马替尼400mg每日两次联合吉非替尼250mg每日一次。
- Ib/II期总体ORR为27%,MET基因拷贝数≥6患者II期ORR为47%。
- 常见药物相关3/4级不良事件为淀粉酶和脂肪酶升高(各6%)。
核心结论
- 卡马替尼联合吉非替尼在EGFR突变伴MET失调的NSCLC中显示出有前景的疗效,尤其对MET扩增疾病。
研究设计与样本
- II期100例患者接受II期推荐剂量治疗。
- 主要终点为按RECIST 1.1评估的客观缓解率(ORR)。
主要发现
- Ib/II期总体ORR为27%。
- II期MET基因拷贝数≥6的患者ORR为47%。
- 常见药物相关不良事件包括恶心(28%)、外周水肿(22%)、食欲下降(21%)和皮疹(20%)。
- 常见药物相关3/4级不良事件为淀粉酶和脂肪酶升高(各6%)。
- 卡马替尼与吉非替尼之间无明显药物相互作用。
关键数值与推荐
- II期推荐剂量为卡马替尼400mg每日两次联合吉非替尼250mg每日一次。
- 主要终点ORR按RECIST 1.1评估。
临床怎么用
- 对于EGFR-TKI治疗后进展且MET扩增/过表达的EGFR突变NSCLC患者,可考虑卡马替尼联合吉非替尼治疗。
- 治疗期间需监测淀粉酶、脂肪酶及恶心、外周水肿等不良反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: MET dysregulation occurs in up to 26% of non-small-cell lung cancers (NSCLCs) after epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment. Capmatinib (INC280) is a potent and selective MET inhibitor with preclinical activity in combination with gefitinib in EGFR-mutant, MET-amplified/overexpressing models of acquired EGFR-TKI resistance. This phase Ib/II study investigated the safety and efficacy of capmatinib plus gefitinib in patients with EGFR-mutated, MET-dysregulated (amplified/overexpressing) NSCLC who experienced disease progression while receiving EGFR-TKI treatment. METHODS: Patients in phase Ib received capmatinib 100- to 800-mg capsules once per day or 200- to 600-mg capsules or tablets twice per day, plus gefitinib 250 mg once per day. Patients in phase II received the recommended phase II dose. The primary end point was the overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. RESULTS: Sixty-one patients were treated in phase Ib, and 100 were treated in phase II. The recommended phase II dose was capmatinib 400 mg twice per day plus gefitinib 250 mg once per day. Preliminary clinical activity was observed, with an ORR across phase Ib/II of 27%. Increased activity was seen in patients with high MET-amplified tumors, with a phase II ORR of 47% in patients with a MET gene copy number ≥ 6. Across phases Ib and II, the most common drug-related adverse events were nausea (28%), peripheral edema (22%), decreased appetite (21%), and rash (20%); the most common drug-related grade 3/4 adverse events were increased amylase and lipase levels (both 6%). No significant drug-drug interactions between capmatinib and gefitinib were evident. CONCLUSION: This study, focused on a predominant EGFR-TKI resistance mechanism in patients with EGFR-mutated NSCLC, shows that the combination of capmatinib with gefitinib is a promising treatment for patients with EGFR-mutated, MET-dysregulated NSCLC, particularly MET-amplified disease.
引用
- Wu YL, Zhang L, Kim DW, et al. Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer. J Clin Oncol. 2018. PMID: 30156984. doi:10.1200/JCO.2018.77.7326
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。